In this slide show we highlight some of the top news on hematologic cancers in 2017, including effective therapies for pediatric hematologic malignancies, a variety of FDA approvals, new discoveries in myeloma, and more.
Hematologic Malignancies Year in Review 2017
Myeloproliferative Neoplasms: Translating New Discoveries Into Better Outcomes, Better Quality of Life
In this review, we demonstrate the evolving landscape of clinical investigation as researchers and clinicians attempt to address the important therapeutic needs of patients with myeloproliferative neoplasms.
Over recent years, there has been much progress in elucidating the biology of these lymphomas, and this has paved the way for novel therapies that are currently under investigation in clinical trials.
‘7+3’ Still Remains the Best Option for Most Patients
Acute myeloid leukemia (AML) is a heterogeneous disorder, with subgroups best classified by discrete mutations detectable by cytogenetic or molecular genetic
As we learn more about the biology of AML, it appears that 7+3 only rarely clears residual leukemic clones in patients with higher-risk disease. New therapies are needed that can target and eradicate resistant subclones early in the disease course.
A 60-Year-Old Man With Progressive Anemia While Receiving Checkpoint Blockade Therapy for Relapsed Myelofibrosis
A 60-year-old man with a history of coronary artery disease and JAK2 V617F–positive polycythemia vera presented to our bone marrow transplantation clinic with progressive fatigue, splenomegaly, and cytopenias.
Here we outline the most promising novel cellular immune strategies for patients with multiple myeloma. In addition, we highlight combinatorial approaches that, it is hoped, will further optimize cellular immunotherapies for myeloma and lead to deep and durable responses and, possibly, even cures.